Guardant Health
Conquering Cancer With Data
Conquering Cancer With Data
Guardant Health is a biotechnology company headquartered in the United States, founded in 2012. The company is dedicated to advancing precision medicine and extending cancer-free lifespans for individuals. Guardant Health's groundbreaking approach involves leveraging advanced blood and tissue tests, real-world data, and AI analytics to gain crucial insights into disease mechanisms. Their portfolio includes tests such as Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, GuardantINFINITY, as well as the early-stage cancer screening test Guardant Reveal and the commercially launched Shield test. In December 2023, Guardant Health received a significant $90.70M Post-IPO Equity investment from Baillie Gifford. Guardant Health's dedication to revolutionizing patient care and their recent investment make them a key player in the biotechnology and healthcare industries. With their innovative approach and significant backing, Guardant Health is poised to make a substantial impact in the fight against cancer.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $90.70M | 1 |
|
21 Dec 2023 |
| Post-IPO Equity | $250.00M | - | 22 May 2023 | |
| Post-IPO Debt | $1.00B | - | 16 Nov 2020 | |
| Venture Round | Unknown | 2 |
|
06 Aug 2018 |
| Series E | $360.00M | 9 |
|
11 May 2017 |
No recent news or press coverage available for Guardant Health.
We care about your data, and we'd love to use cookies make your experience better.
